Exciting Developments in Gene Therapy at ASGCT Annual Meeting
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a leading biotechnology firm focusing on genetic treatments for neurological disorders, recently announced its participation in the American Society of Gene & Cell Therapy’s (ASGCT) 28th annual meeting. This event will showcase substantial advancements made in gene therapies, particularly in tackling Alzheimer's disease.
At this convention, which is scheduled to occur in May, Voyager will present eight oral and poster presentations detailing their pioneering research, including their tau silencing gene therapy, VY1706. Prior studies have demonstrated impressive results, achieving up to 73% knockdown of tau mRNA in non-human primates following a single intravenous dose. Highlighting the versatility of Voyager's TRACER capsids, data will also be showcased on innovative anti-amyloid gene therapies aimed at providing efficient treatment pathways for neurological conditions.
Achievements in CNS Penetration
Voyager's Chief Scientific Officer, Todd Carter, expressed pride in the significant capabilities of their TRACER capsids, which have been shown to transduce between 43% to 98% of neurons and 87% to 99% of astrocytes throughout diverse brain regions after just one intravenous administration. At ASGCT, the company aims to further exemplify its commitment to groundbreaking research in the field. The continued enhancements seen such as immune evasion strategies could potentially widen the demographic of patients eligible for these advanced treatments.
Oral Presentation Highlights
- VY1706 Presentation: Dr. Rajeev Sivasankaran will lead an oral presentation on the intravenous delivery of VY1706, emphasizing its effectiveness in lowering tau levels in the central nervous system (CNS).
- Research on Cross-Species Applications: Dr. Hechen Bao will discuss cross-species efficacy, showcasing the capability of the gene therapy to provide robust tau lowering benefits in both murine models and non-human primates.
- Innovative Anti-Amyloid Strategy: A unique one-time delivery method for an anti-amyloid antibody will also be presented, focusing on sustained CNS expression and heightened engagement with targets.
Focus on Capsid Development
In addition to gene therapy advancements, Voyager dedicates efforts to refining its TRACER capsid discovery platform. This platform signifies a breakthrough in gene therapy through rapid identification of novel AAV capsids conducive to effective gene delivery. Characteristics such as low-dose efficacy and efficiency further highlight the potential of Voyager's innovations in treating complicated neurological disorders.
Reducing Immunogenicity
- On May 14, discover how AAV9-derived CNS capsids can avoid pre-existing neutralizing antibodies through a presentation by Damien Maura.
- Machine-learning techniques to optimize AAV9 capsid screening for improved production and transduction efficiency will be discussed by Dr. Daniel Cox.
- Improvement strategies for AAV yield via HEK293 cell line cloning will also be featured, along with anion exchange chromatography as a method for capsid enrichment.
These presentations signify a collective goal to enhance the delivery capabilities of gene therapies, which could yield substantial benefits for patients suffering from debilitating neurological diseases.
About Voyager Therapeutics
Voyager Therapeutics, Inc. (Nasdaq: VYGR) is radically transforming the therapeutic landscape for neurological diseases by leveraging human genetics. Their extensive pipeline encompasses treatments for various conditions including Alzheimer’s, Friedreich’s ataxia, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS). By employing their innovative TRACER™ platform, Voyager has been able to formulate new capsids and identify receptors crucial for achieving optimal brain penetration when administering genetic therapies.
Frequently Asked Questions
What is the significance of the presentations at ASGCT?
The presentations at ASGCT showcase Voyager's innovative research in gene therapies, emphasizing their potential impact on treating Alzheimer's disease.
What research will be highlighted by Voyager Therapeutics?
Voyager will highlight two main areas: their tau silencing gene therapy VY1706 and anti-amyloid gene therapy, both aimed at addressing key challenges in Alzheimer’s treatment.
How do TRACER capsids improve gene therapy effectiveness?
The TRACER capsids enhance gene therapy effectiveness by enabling superior CNS penetration, allowing for targeted delivery to brain cells and addressing neurological conditions more effectively.
Who will be presenting at the ASGCT meeting?
The presentations will be delivered by various internal experts, including Dr. Rajeev Sivasankaran and Dr. Hechen Bao, among others.
What neurological diseases does Voyager Therapeutics target?
Voyager targets several neurological diseases, including Alzheimer’s, Friedreich’s ataxia, and Parkinson’s disease, with a strong focus on genetic therapy innovations.
